Kassis-George Kassis-George

Dr. Kassis-George Kassis-George

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in Pulmonary Therapy
Verified
Journal Article
Open access
PDF file
KKKassis-George Kassis-George
Kassis-George Kassis-George
CLCandice Lee
Candice Lee
MCMithun Chakravarthy
Mithun Chakravarthy
MKManreet Kanwar
Manreet Kanwar
Chronic thromboembolic pulmonary disease (CTEPD) is characterized by unresolved clot burden in large pulmonary arteries, obstructive disease in smaller arteries, and increased downstream clot burden. This occurs in the setting of abnormal fibrinolysis or hematological disorders. Up to 50% of patients in some studies are unaware of a self-history of a deep venous thrombosis or pulmonary embolism. Ultimately, they present with symptoms of pulmonary hypertension (PH), which can result in right heart failure (RHF). Pulmonary endarterectomy (PEA) is curative, though many patients have prohibitive surgical risk or surgically inaccessible disease, warranting other interventions such as balloon pulmonary angioplasty (BPA) and medical therapy. Rarely, other treatment options may be implemented. We focus this review on PEA and BPA, with an overview of the history of CTEPD and the evolution of these procedures. We will briefly discuss other treatment modalities.

5 December 2022 in Clinical Case Reports
Verified
Journal Article
Open access
MDMatthew Deicke
Matthew Deicke
LALaith Alhuneafat
Laith Alhuneafat
OOOmar Obaid
Omar Obaid
AAAderonke Adeniyi
Aderonke Adeniyi
ARAmresh Raina
Amresh Raina
KKKassis-George Kassis-George
Kassis-George Kassis-George
A 54‐year‐old man status post heart and kidney transplant presented with dyspnea. Imaging was consistent with lymphangitic carcinomatosis (LC), in the setting of biopsy proven adenocarcinoma. He developed pulmonary hypertension (PH) and died of right ventricular failure (RVF) 3 weeks later. Acute PH with radiographic features of LC in a high‐risk patient warrants expedited malignancy investigation.

26 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PAPushan Aggarwal
Pushan Aggarwal
AYAishwarya Yannamani
Aishwarya Yannamani
JJJyoti Jain
Jyoti Jain
IKIlija Klipa
Ilija Klipa
AOAndrew Oehler
Andrew Oehler
KKKassis-George Kassis-George
Kassis-George Kassis-George
Cardiac rehabilitation (CR) is a multicomponent secondary prevention intervention that improves functional capacity and quality of life across cardiac diagnoses, yet remains markedly underused in heart failure (HF). Existing reviews treat efficacy, coverage, delivery, and equity separately; this narrative review integrates them to clarify why uptake in HF remains low despite an established evidence base. We searched PubMed/MEDLINE and the Cochrane Library from January 2009 through December 2025, prioritizing clinical practice guidelines, landmark trials, systematic reviews, registry analyses, and U.S. policy documents, with narrative synthesis across efficacy, coverage, delivery, and equity. In heart failure with reduced ejection fraction (HFrEF), exercise-based CR consistently improves peak oxygen consumption by roughly 15 to 17 percent, improves health status, and reduces short-term all-cause hospitalization. In heart failure with preserved ejection fraction (HFpEF), supervised exercise improves functional capacity and quality of life, but a large pragmatic outcome trial and Medicare coverage remain lacking. In appropriately selected, clinically stable patients, hybrid and virtual delivery produce comparable short-term functional and quality-of-life gains, with more limited direct evidence for hard clinical endpoints. Closing the HFpEF coverage gap, automating HFrEF referral, diversifying delivery, and embedding equity across the CR pipeline are actionable priorities for realizing CR’s potential in HF.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
RKRahul Karna
Rahul Karna
PAPalash Asawa
Palash Asawa
TMTanveer Ud-Din Mian
Tanveer Ud-Din Mian
ANAdeel Nasrullah
Adeel Nasrullah
ARAmresh Raina
Amresh Raina
KKKassis-George Kassis-George
Kassis-George Kassis-George
There is a well-established association between obesity and various forms of pulmonary hypertension (PH). In recent years, our understanding of the role of obesity in the development of PH has changed significantly. In addition to its indirect contribution via effects on the cardiopulmonary system, obesity is now implicated in the development of pulmonary arterial hypertension (PAH) via insulin resistance, systemic inflammation and endothelial dysfunction. Weight loss improves pulmonary artery pressures, implicating weight loss as a potential strategy to improve PH. There is preliminary evidence of improvement in PH with bariatric surgery in obese patients. Here, we describe the role of obesity in PH, and discuss weight loss, and bariatric surgery, as a potential management strategy for PH.

1 January 2025 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
SASaed Alnaimat
Saed Alnaimat
MMMariah Mascara
Mariah Mascara
CLCandice Lee
Candice Lee
KKKassis-George Kassis-George
Kassis-George Kassis-George
Alnaimat S, et al. Int J Heart Fail. 2025 Jan;7(1):1-5. https://doi.org/10.36628/ijhf.2024.0053